FindTrial
Sign In

Evaluation of the effect of squill oxymel In asthma

Evaluation the effect of squill oxymel, Traditional Medicine product, in the treatment of moderate to severe asthma in patients 18 to 70 years old: triple-blind randomized Clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014111119912N1
Enrollment
51
Registered
2015-02-12
Start date
2015-02-14
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma. asthma

Interventions

Intervention 1: Intervention Group1 (Medication): Squill Oxymel (traditional medicine products)Oral Syrup (250ml), 10 ml twice a day for 6 weeks. Intervention 2: Intervention Group2 (Medication): simp
Treatment - Drugs
Placebo
Intervention Group1 (Medication): Squill Oxymel (traditional medicine products)Oral Syrup (250ml), 10 ml twice a day for 6 weeks
Intervention Group2 (Medication): simple Honey OxymelOral Syrup (250ml), 10 ml twice a day for 6 weeks
Control Group (placebo): a mixture of honey, water, color additive, etc. Oral Syrup (250ml), 10 ml twice a day for 6 weeks

Sponsors

College of Traditional Medicine of Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age 18 to 70 years; asthma patients with moderate to severe asthma who have clinical criteria include: FEV1 between 40% to 80% of the predicted and asthma that was insufficiently controlled despite treatment with medium or high dose inhaled corticosteroids; treated with conventional drugs; Lack of pregnancy; Lack of breastfeeding; Lack of the use other herbal medicines; Lack of active peptic ulcer and cardiovascular disease (especially heart block) or renal disease; Not concomitant use of anticoagulant; Non-smoking. Exclusion criteria: Add or remove the drugs that interferes with asthma (such as NSAIDs); Infections leading to hospitalization; the patient's unwillingness to continue treatment.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Asthma quality of life. Timepoint: Before and after the intervention (end of week 6). Method of measurement: St. George's Respiratory Questionnaire (SGRQ).;FEV1. Timepoint: Before and after the intervention (end of week 6). Method of measurement: Spirometry testing.—

Secondary

MeasureTime frame
FEV1/FVC. Timepoint: Before and after the intervention (end of week 6). Method of measurement: Spirometry testing.;RV (Residual Volume). Timepoint: Before and after the intervention (end of week 6). Method of measurement: body box plethysmography.;TLC (total lung capacity). Timepoint: Before and after the intervention (end of week 6). Method of measurement: body box plethysmography.;RV/TLC. Timepoint: Before and after the intervention (end of week 6). Method of measurement: body box plethysmography.;RAW total (Resistance Air Way total). Timepoint: Before and after the intervention (end of week 6). Method of measurement: body box plethysmography.;RAW in, ex (Resistance Air Way). Timepoint: Before and after the intervention (end of week 6). Method of measurement: body box plethysmography.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Hossein Karegar-Borzi

Tehran University of Medical Sciences

h-karegar@razi.tums.ac.ir+98 21 5563 9724

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026